By Blake Brittain (Reuters) - A federal jury on Tuesday found that Gilead Sciences Inc did not infringe U.S. patents with its HIV-prevention regimen u.
Gilead Sciences Inc is headed
to trial in Delaware federal court this week to fight claims
that it owes the U.S. government a share of multibillion-dollar
profits from its HIV-prevention drug. | May 2, 2023
In partnering with clinical-stage Arcellx, Gilead Sciences gains the opportunity to develop a cell therapy for multiple myeloma that could offer advantages over currently available therapies for the blood cancer. The deal announced Friday came as Arcellx reported additional data during the annual meeting of the American Society of Hematology that showed continued durability of the cell therapy.
The generic drugmakers argued that the patents were invalid and unenforceable. They said in an August court filing that Gilead s patents covered "routine and predictable" variants of a "compound it.